Celecoxib (Celebrex).
Celecoxib is a COX-2 selective NSAID used for pain and inflammation. It contains a sulfonamide group, which led the original product labelling to caution against use in patients with sulfa allergy. Subsequent published evidence has reduced confidence in that strict avoidance: cross-reactivity with sulfa antibiotic allergy is low, and many patients with such labels tolerate celecoxib without reaction.
- Class
- COX-2 selective non-steroidal anti-inflammatory drug (NSAID).
- Brand
- Celebrex (most common); generic celecoxib widely available.
- Common indications
- Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, dysmenorrhoea.
- Sulfa allergy
- Original label cautioned avoidance; modern evidence suggests cross-reactivity is low.
What it does
Cyclooxygenase (COX) enzymes convert arachidonic acid to prostaglandins, which mediate pain, inflammation, and fever. Two main isoforms exist: COX-1 (constitutive in many tissues, including the gastric mucosa, where its prostaglandins protect the stomach lining) and COX-2 (inducible, prominent at sites of inflammation). Celecoxib selectively inhibits COX-2 over COX-1.
The clinical aim of COX-2 selectivity was to retain the anti-inflammatory and analgesic effects of NSAIDs while reducing their gastrointestinal toxicity. Studies have largely supported a reduction in serious gastrointestinal events compared with non-selective NSAIDs, though the cardiovascular safety story has been more complicated and is the source of much of the regulatory and clinical history around the COX-2 class.
What it is used for
Osteoarthritis and rheumatoid arthritis — chronic pain and inflammation control. Ankylosing spondylitis — symptom control. Acute pain — short-course use for postoperative pain or musculoskeletal injury. Dysmenorrhoea — menstrual pain. Familial adenomatous polyposis — historical adjunctive use to reduce polyp burden, narrower today.
Choice of NSAID depends on the indication, the patient's cardiovascular and gastrointestinal risk, kidney function, age, and other drugs. For patients at higher gastrointestinal risk on chronic NSAID therapy, celecoxib is one option; alternatives include non-selective NSAIDs combined with proton pump inhibitor therapy.
Common adverse effects
NSAID-class effects mostly apply: dyspepsia, abdominal discomfort, fluid retention, hypertension elevation, kidney effects (particularly in older patients, those with reduced GFR, or those on ACE inhibitors and diuretics — the "triple whammy"), and rare hepatic injury. Cardiovascular risk is a class concern with COX-2 selective NSAIDs and with non-selective NSAIDs, and the absolute risk depends on dose, duration, and patient factors. Gastrointestinal ulceration and bleeding are reduced compared with non-selective NSAIDs but not eliminated.
Allergic-type reactions to celecoxib include rashes, occasional photosensitivity, and rare severe cutaneous reactions including Stevens-Johnson syndrome (very rare). Patients with aspirin-exacerbated respiratory disease (AERD, the asthma-NSAID-nasal polyp triad) should generally avoid all NSAIDs; COX-2 selectives are sometimes tolerated in this group but should not be assumed safe without specialist input.
The sulfa allergy story
Celecoxib's structure includes a sulfonamide group attached to a phenyl ring. It does not have the N4 arylamine that drives most antibiotic-type immune reactivity. The original product labelling, drafted in the era when "sulfa allergy" was treated as a class-wide concern, listed sulfa allergy as a contraindication or strong caution.
Subsequent evidence — including studies that specifically challenged sulfa-allergic patients with celecoxib — has shown low rates of cross-reaction. Updated guidance and product information in many jurisdictions have softened the original wording, though the historical caution still appears in some prescribing information. The reasoning is on antibiotic vs non-antibiotic sulfonamides; the broader picture is on cross-reactivity.
In current practice, most prescribers will consider celecoxib in patients with a documented mild sulfa antibiotic allergy where COX-2 selectivity is desired and the patient does not have other contraindications. Patients with severe past reactions to sulfa antibiotics — Stevens-Johnson syndrome, TEN, anaphylaxis — are managed cautiously and often offered a non-sulfonamide NSAID instead.
Interactions and cautions
Celecoxib is metabolised primarily by CYP2C9 and has interactions with drugs that share that pathway, including warfarin and fluconazole. Patients who are CYP2C9 poor metabolisers may have higher drug exposure. Routine NSAID interactions apply: caution with ACE inhibitors, ARBs, lithium, methotrexate, and certain antidepressants (with bleeding risk). Cardiovascular history, kidney function, and concomitant medications shape prescribing.